{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(5)"],"submitter":["Lee JH"],"funding":["Center for Preparedness and Response","Sorokdo National Hospital","Ministry of Health and Welfare"],"pubmed_abstract":["Brain inflammation generally accelerates neurodegeneration. Alzheimer's disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4'-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD."],"journal":["iScience"],"pagination":["104274"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9079171"],"repository":["biostudies-literature"],"pubmed_title":["Dapsone is an anticatalysis for Alzheimer's disease exacerbation."],"pmcid":["PMC9079171"],"pubmed_authors":["Sergi C","Coleman MD","Kanwar B","Lee CJ","Lee JH"],"additional_accession":[]},"is_claimable":false,"name":"Dapsone is an anticatalysis for Alzheimer's disease exacerbation.","description":"Brain inflammation generally accelerates neurodegeneration. Alzheimer's disease (AD) triggers an innate immune response by activating a cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway. Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4'-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone. T2:T3 proved that the prevalence of AD was significantly high without dapsone. T1:T4 proved that the prevalence decreased when taking dapsone. Our study demonstrates that dapsone can prevent AD exacerbation and may represent a preventive therapeutic option for exacerbated AD.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-31T01:10:37.684Z","creation":"2024-10-16T14:46:24.191Z"},"accession":"S-EPMC9079171","cross_references":{"pubmed":["35542045"],"doi":["10.1016/j.isci.2022.104274"]}}